Potential For New Generation Of Anticoagulants And Improving The Fight Against The Spread Of Malaria
12/14/2012
An international project lead by the Molecular and Cell Biology Institute of Porto University with the participation of researchers from IMIM (Hospital del Mar Medical Research Institute) has, for the first time ever, deciphered the mechanism by which a substance called anophelin binds to an enzyme (thrombin) involved in the process of blood coagulation...
In Melanoma, Suppressive Factors Need To Be Blocked For More Effective Immunotherapy
12/14/2012
Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them...
Predicting Risk In Hodgkin Disease Via Blood Levels Of Immune Protein
12/14/2012
Blood levels of an immunity-related protein, galectin-1, in patients with newly diagnosed Hodgkin lymphoma reflected the extent of their cancer and correlated with other predictors of outcome, scientists reported at the American Society of Hematology annual meeting...
Phase 3 Trial Finds Experimental Graft-Vs.-Host Disease Treatment Equivalent To Standard Care
12/14/2012
An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting...
New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib* in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA...
Clavis Pharma ASA (OSE: CLAVIS), the Norwegian cancer drug development company, announces data from its Phase II clinical trial with elacytarabine in combination with idarubicin...
For Patients With Aggressive Chronic Lymphocytic Leukemia, Ibrutinib, Rituximab Deliver A 1-2 Punch
12/13/2012
A two-prong approach combining ibrutinib and rituximab (Rituxin®) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center. Researchers presented the results at the 54th annual meeting of the American Society of Hematology (ASH)...
Children With Very High Risk Form Of Leukemia May Benefit From Intensified Chemotherapy
12/13/2012
Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston...
Breast Cancer Survivors More Likely To Develop Diabetes
12/13/2012
Survivors of breast cancer, who are post-menopausal, have a higher chance of developing breast cancer. The new study, published in Diabetologia, is the largest yet to observe this link between surviving breast cancer and eventually developing diabetes; it also showed that whether the patient went on to develop diabetes was closely associated with her having undergone chemotherapy...
Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers...